Objective: To determine whether vascular endothelial growth factor (VEGF) levels are associated with the presence of cerebral microbleeds (CMBs) in patients after acute ischemic stroke.
C EREBRAL MICROBLEEDS
(CMBs) are focal perivascular collections of blood breakdown products and are visualized as small areas of signal loss on T2*-weighted gradient echo magnetic resonance image (MRI) sequences. 1 Cerebral microbleeds are commonly found in patients with ischemic stroke or primary intracerebral hemorrhage; histologically, they are found adjacent to small vessels affected by hypertensive arteriopathy or cerebral amyloid angiopathy. [2] [3] [4] Cerebral microbleeds are found in approximately 30% of patients with acute ischemic stroke. 5 An MRI follow-up study found that about 25% of patients with ischemic stroke/transient ischemic attack developed new CMBs after 5 years. 6 Recent data have shown that CMBs develop within days of acute ischemic stroke, remote from the symptomatic acute infarct, 3 but the mechanisms underpinning new CMB formation remain unknown. Although CMBs are known to be associated with focal small-vessel damage, 1 another potential contributing factor is an active widespread microangiopathy with leakage of the blood-brain barrier.
Vascular endothelial growth factor (VEGF) is a potent angiogenic glycoprotein that is upregulated as a result of the ensuing hypoxia after an acute ischemic stroke 7 ; VEGF has an important role in the control of vascular permeability. 8 To investigate the hypothesis that VEGF plays a role in the formation of CMBs in acute ischemic stroke, we compared VEGF levels of patients with CMBs with those without CMBs.
METHODS

PATIENTS
Serum VEGF levels were determined in 20 patients with clinically and radiologically confirmed acute ischemic stroke. We prospec-tively recruited all patients within 24 hours of symptom onset from the Accident and Emergency Department at University College Hospital, London. Serum VEGF levels were also measured in 15 healthy control subjects with no medical history of stroke (7 [47%] 
LABORATORY ANALYSIS
Venous samples were obtained from patients on admission. Blood was centrifuged within 30 minutes of collection (1500g for 10 minutes), and the serum was frozen at −80°C for later analysis. The VEGF levels were analyzed using sandwich enzyme-linked immunoassay (assay sensitivity, Ͻ5 pg/mL [range, 23-1500 pg/mL]; Invitrogen UK).
IMAGING PROTOCOL
Magnetic resonance imaging, including axial T2-weighted fast spin echo and axial gradient-recalled echo T2* sequences, was carried out at 1.5-T field strength using 2 MRI systems: (1) the Genesis Signa system (GE Healthcare) and (2) the Magnetom Avanto system (Siemens). The axial gradient-recalled echo T2* sequence settings were as follows: Genesis Signa system: repetition time, 300 milliseconds; echo time, 40 milliseconds; flip angle, 20°; field of view, 24ϫ18 pixels; matrix, 256ϫ160 pixels; section thickness, 5 mm; section gap, 1.5 mm; number of excitations, 1; Magnetom Avanto system: repetition time, 800 milliseconds; echo time, 26 milliseconds; flip angle, 20°; field of view, 24ϫ18 pixels; matrix, 512ϫ448 pixels; section thickness, 5 mm; section gap, 1.5 mm; number of excitations, 1.
IMAGE ANALYSIS
The image analysis was performed with the rater (S.M.G.) blind to VEGF levels and clinical details. A validated CMB rating scale was used by a trained observer (S.M.G.). 9 
RESULTS
All 20 patients underwent MRI within 5 days of acute ischemic stroke; 5 (25%) had at least 1 CMB. The CMBs were located distant from the index (recent) infarct in each patient (Figure 1) . Eleven CMBs were noted: 3 in infratentorial regions (1 cerebellar and 2 brainstem), 2 in deep regions (thalamus), and 6 in lobar regions. When patients with and without CMBs were compared, there was no significant difference between the 2 groups with respect to age, sex, National Institute of Health Stroke Scale (NIHSS) score, infarct volume, or the prevalence of vascular risk factors (Table) .
The median VEGF concentration in the patients experiencing stroke, irrespective of the presence of CMBs, was significantly higher than that in the healthy controls (2010 vs 546 pg/mL; P Ͻ .001). The median VEGF level in the group with CMBs was significantly higher than the level in the group without CMBs (P = .003, MannWhitney test) (Figure 2) . Even when the outlier in the cohort with CMBs was excluded, the difference remained statistically significant (P = .01, Mann-Whitney test). The patient with the highest serum VEGF level (9813 pg/mL) also had the most CMBs (n = 6). We noted a modest correlation between serum VEGF level and maximum NIHSS score (r = 0.339; P = .02).
COMMENT
Our results show that VEGF levels were significantly higher in patients who experienced ischemic stroke with CMBs compared with those without CMBs. In agreement with previous reports, 7 we also confirm that VEGF levels in patients with acute ischemic stroke are significantly elevated compared with levels in healthy controls. Confounding factors-in particular, infarct volume and stroke severity 7 -are unlikely to account for the difference in serum VEGF expression between the groups with and without CMBs because the groups did not differ with respect to these characteristics.
It is generally assumed that, to form CMBs, blood degradation products must leak from focal damage, increasing the fragility of small vessels. However, CMBs are not an invariable consequence of pathologic damage to such vessels. Thus, in addition to structural small-vessel damage, 1 there may be other triggers for vascular leakage in the pathogenesis of CMBs in some patients. One possibility is that abnormal vascular permeability could potentiate CMB formation. Vascular endothelial growth fac- Abbreviations: CMB, cerebral microbleed; NIHSS, National Institute of Health Stroke Scale.
a There was no significant difference between the 2 groups for any of the characteristics.
b The maximum total NIHSS score is 42. . A statistically significant difference existed between these 2 subgroups (P = .003). This difference remained significant even after excluding the outlier high VEGF value from the group with CMBs (P = .01).
tor, a potent inducer of vascular leakage, 8 is upregulated after acute ischemic stroke 7 and may trigger or potentiate CMB genesis. Animal model studies have also shown that hypoxia-induced VEGF surges in the brain can exacerbate vascular leakage. 10 Strengths of our study include the recruitment of patients with imaging-proved ischemic stroke and the use of a validated microbleed rating scale by a rater blind to both the clinical data and the VEGF levels. In addition, although our study was small, the difference in VEGF levels between patients with and without CMBs was highly significant (P = .003). However, because this was a crosssectional study, it is difficult to infer causality, that is, whether elevated VEGF levels were a cause or an effect of a CMB-associated cerebral microvasculopathy. Furthermore, because we have MRIs from a single time point only, we cannot determine how many of the CMBs observed occurred after rather than before the ischemic stroke. Finally, although the intergroup differences in serum VEGF level do not appear to be driven by the small differences in stroke volume or NIHSS score, our sample size is not large enough to adjust for these potential confounding factors. This study should therefore be considered preliminary: it needs to be extended to larger cohorts of patients with acute stroke in which serial MRI is used to establish the consistency of our findings and to clarify whether high VEGF levels are independently associated with new CMB formation.
Agents to pharmacologically block the harmful effects of an increased VEGF level, including vascular leakage, after cerebral ischemia are of current interest. Our findings suggest that studies of such treatments might usefully incorporate MRI to monitor the development of CMBs. Furthermore, VEGF level, as a potential marker for vascular leakage and microbleeding, deserves further investigation as a prognostic marker for bleeding risk in acute stroke (eg, before thrombolytic therapy). 
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